Lesson
Trace the Mold From Airway to Tissue
Aspergillus conidia are inhaled every day. Disease emerges from the interaction among fungal form, airway structure, immune defense, and the affected compartment.
- Conidia
- Septate hyphae
- Acute-angle branching
- Angioinvasion
- Host defense
biology syndromes
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Follow the fungal form
Airborne conidia reach the airway and may be cleared, colonize abnormal spaces, trigger allergic inflammation, or germinate into hyphae. In tissue, septate hyphae with acute-angle branching support Aspergillus but do not always establish species.
Understand invasion
Neutrophils and macrophages are central defenses. When these systems fail, hyphae can invade vessels, causing thrombosis, hemorrhage, infarction, and hematogenous dissemination.
Map the disease spectrum
The same genus can be associated with ABPA, airway colonization, a fungal ball in a preexisting cavity, chronic cavitary disease, invasive pulmonary disease, or extrapulmonary invasion.
Preserve diagnostic options
Coordinate tissue so pathology can demonstrate invasion while a fresh portion remains available for culture and molecular testing.
Quick check
Lesson
Define Risk Before the First Symptom
Invasive disease risk rises with prolonged neutropenia, hematologic malignancy, transplantation, corticosteroids, and other major immune impairment.
- Neutropenia
- Hematologic malignancy
- HSCT
- Solid-organ transplant
- Corticosteroids
host prevention
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Quantify immune risk
Record neutrophil depth and expected duration, transplant type and timing, graft-versus-host disease, rejection treatment, corticosteroid dose, targeted therapies, and prior mold infection.
Reduce environmental exposure
Protected environments, construction separation, and avoidance of gardening, mulch, compost, and renovation dust are reasonable for highly immunocompromised patients.
Use prophylaxis selectively
Mold-active prophylaxis depends on population, institutional incidence, prior infection, interactions, toxicity, absorption, and stewardship. A universal approach is not evidence-based for every host.
Plan secondary prevention
A patient successfully treated for invasive disease who will undergo further immunosuppression may require secondary prophylaxis to prevent recurrence.
Quick check
Lesson
Build Evidence Across Host, Image, and Specimen
No single test establishes invasive aspergillosis in every host. High-quality diagnosis combines CT, bronchoscopy or tissue, microscopy, culture, biomarkers, and prior antifungal exposure.
- Chest CT
- BAL
- Histopathology
- Galactomannan
- Beta-D-glucan
diagnostic evidence
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Start with CT
Obtain chest CT when invasive pulmonary disease is suspected even if chest radiography is normal. Nodules, surrounding ground-glass change, wedge-shaped lesions, consolidation, cavitation, and airway-centered patterns guide the next procedure.
Sample the compartment
Attempt bronchoscopy with BAL when safe. Send BAL for fungal culture, cytology, galactomannan, and locally validated molecular testing. Peripheral nodules may require image-guided tissue rather than BAL alone.
Interpret biomarkers by population
Serum and BAL galactomannan are most useful in selected high-risk groups. Mold-active prophylaxis, host type, specimen, timing, and false positives change performance.
Keep beta-glucan nonspecific
Beta-D-glucan supports possible invasive fungal disease but does not identify Aspergillus and can be affected by other infections and clinical exposures.
Quick check
Lesson
Name the Syndrome Before Treating
A respiratory Aspergillus result can represent contamination, colonization, allergic disease, a fungal ball, chronic disease, or invasion.
- Colonization
- ABPA
- Aspergilloma
- CCPA
- Invasive disease
syndrome separation
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Do not equate culture with invasion
A positive respiratory culture can reflect colonization. Invasion requires compatible clinical and radiographic disease with tissue or mycologic evidence interpreted in the host.
Recognize allergic disease
ABPA is an immune-mediated airway disorder commonly associated with asthma, cystic fibrosis, or bronchiectasis. Sensitization, total IgE, eosinophilia, mucus plugging, and imaging define the model.
Recognize cavity syndromes
An aspergilloma is a mobile fungal ball within a preexisting cavity. Chronic cavitary pulmonary aspergillosis requires at least three months of symptoms or progression, characteristic imaging, and Aspergillus IgG or other microbiologic evidence.
Recognize invasion
Fever, pleuritic pain, hemoptysis, hypoxemia, nodules or infarcts, and progressive disease in a high-risk host demand urgent invasive-disease evaluation.
Quick check
Lesson
Start Mold-Active Therapy Early
Primary invasive pulmonary aspergillosis therapy is voriconazole for most patients. Isavuconazole and liposomal amphotericin B are important alternatives.
- Voriconazole
- Isavuconazole
- Liposomal amphotericin B
- Early therapy
- 6 to 12 weeks
primary treatment
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Use primary voriconazole
For a seriously ill adult, load voriconazole 6 mg/kg IV every 12 hours for two doses, then 4 mg/kg IV every 12 hours. Transition to an appropriate oral regimen when stable and absorbing reliably.
Use a justified alternative
Isavuconazole is an FDA-approved alternative primary therapy. Liposomal amphotericin B is useful when azoles are unsafe, unreliable, resisted, or when Mucorales remains a serious competing diagnosis.
Avoid fluconazole
Fluconazole lacks reliable Aspergillus activity. Echinocandins are not routine stand-alone primary therapy.
Set the duration dynamically
Treat for at least 6 to 12 weeks, then extend according to immune recovery, site, imaging, organism evidence, tolerability, and continued immunosuppression.
Quick check
Lesson
Engineer Voriconazole Exposure
Voriconazole succeeds only when loading, route, nonlinear exposure, genetics, interactions, TDM, and toxicity are managed as one system.
- Loading
- CYP2C19
- Trough
- SBECD
- Phototoxicity
voriconazole system
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Dose the phase
Adult invasive-disease loading is 6 mg/kg IV every 12 hours for two doses, followed by 4 mg/kg IV every 12 hours. Current labeling lists 200 mg orally every 12 hours for most adults, with weight and response adjustments.
Measure exposure
Variable absorption and nonlinear metabolism make a steady-state trough useful. RxPrep teaches a practical trough range of 1 to 5 mcg/mL, but the result must be interpreted with assay, timing, response, and toxicity.
Respect route and renal function
The intravenous vehicle SBECD can accumulate when creatinine clearance is below 50 mL/min. Oral voriconazole does not contain SBECD, so route selection requires a benefit-risk assessment rather than rejection of the drug class.
Monitor the whole toxicity profile
Track liver tests, visual and neurologic effects, photosensitivity, skin cancer risk with prolonged exposure, QT and electrolyte risk, periostitis, and CYP-mediated interactions.
Quick check
Lesson
Choose Alternatives by Failure Mechanism
A change in therapy should answer why the original plan failed: wrong mold, resistance, inadequate exposure, intolerance, progression, or an uncontrolled site.
- Isavuconazole
- Liposomal amphotericin B
- Salvage
- Combination
- Susceptibility
alternatives salvage
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Use isavuconazonium correctly
Load 372 mg IV or orally every 8 hours for six doses, then use 372 mg once daily. It shortens rather than prolongs QT and is contraindicated in familial short QT syndrome.
Use liposomal amphotericin deliberately
Liposomal amphotericin B is a nonazole alternative that preserves Mucorales coverage. Monitor kidney function, potassium, magnesium, CBC, infusion reactions, and nephrotoxic combinations.
Limit echinocandin claims
An echinocandin can be used in selected salvage settings. Voriconazole plus an echinocandin may be considered for selected documented invasive pulmonary disease, but it is not a universal primary regimen.
Test suspected resistance
Obtain susceptibility testing for nonresponse, breakthrough during azole exposure, or epidemiologic concern. Consider species and local azole-resistant A. fumigatus patterns.
Quick check
Lesson
Treat the Compartment and the Anatomy
Pulmonary treatment does not automatically resolve CNS, sinus, cardiac, bone, skin, or ocular disease. Some lesions require surgery or another procedure.
- CNS
- Sinus
- Endocardial
- Bone
- Source control
site source control
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Protect the CNS
Neurologic symptoms require urgent imaging and site-directed evidence. Voriconazole is commonly favored because of CNS activity, while surgery may be needed for selected accessible lesions or mass effect.
Control invasive sinus disease
Combine systemic mold-active therapy with surgical debridement when feasible, especially when necrotic tissue or extension threatens the orbit or brain.
Address structural foci
Endocarditis, infected devices, bone disease, skin lesions, and ocular disease need specialist evaluation, site-specific imaging, tissue, and source-control decisions.
Modify the host
Reduce immunosuppression when feasible, support neutrophil recovery, and correct metabolic or structural factors without provoking rejection or inflammatory harm.
Quick check
Lesson
Manage Chronic and Allergic Disease on Their Own Terms
Chronic pulmonary aspergillosis, aspergilloma, and ABPA require different evidence and treatment from acute invasive disease.
- CCPA
- Aspergillus IgG
- Aspergilloma
- Hemoptysis
- ABPA
chronic allergic
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Define chronic cavitary disease
Require at least three months of symptoms or progression, compatible cavities and pleural change, Aspergillus IgG or microbiologic evidence, and an underlying lung disorder with no or limited immunocompromise.
Treat progressive chronic disease
Symptomatic or progressive chronic cavitary disease is treated with itraconazole or voriconazole for at least six months. Stable minimally symptomatic disease may be observed with follow-up every 3 to 6 months.
Manage aspergilloma and bleeding
Observe selected asymptomatic stable fungal balls. Significant hemoptysis can require tranexamic acid, bronchial-artery embolization, antifungal therapy to reduce recurrence, or surgical resection after risk assessment.
Apply current ABPA guidance
The 2024 ISHAM guideline uses fungal sensitization, total IgE at least 500 IU/mL, plus supporting IgG, eosinophilia, or imaging. Acute symptomatic disease uses oral prednisolone or itraconazole monotherapy, usually over four months, with combination reserved for recurrent exacerbations.
Quick check
Lesson
Prove Response and Investigate Breakthrough
Improvement requires control of fungal burden, recovery of host defense, reliable antifungal exposure, and management of every involved site.
- Imaging
- TDM
- Immune recovery
- Breakthrough
- Azole resistance
response resistance
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Track multiple domains
Follow symptoms, oxygenation, function, imaging, cultures or pathology when available, biomarkers in an appropriate population, antifungal exposure, organ toxicity, and immune recovery.
Expect imaging complexity
Lesions can enlarge transiently during neutrophil recovery. Interpret radiographic change with timing, physiology, immune trajectory, and other evidence rather than declaring failure from size alone.
Audit breakthrough disease
Confirm dose, route, adherence, absorption, trough, interactions, organism, susceptibility, and competing molds. Obtain new site evidence and consider a different antifungal class.
Prevent recurrence
Continue treatment through adequate immune recovery and use secondary prophylaxis when later immunosuppression creates renewed risk.
Quick check
Lesson
Use the 2026 Prevention Update Precisely
The newest IDSA aspergillosis update currently addresses prevention in adult solid-organ transplant recipients and does not replace every 2016 treatment recommendation.
- Liver transplant
- Lung transplant
- Targeted prophylaxis
- Knowledge gap
- Stewardship
transplant prevention
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Avoid universal liver-transplant prophylaxis
The 2026 IDSA update suggests against universal anti-Aspergillus prophylaxis for all liver transplant recipients and supports targeted prophylaxis for high-risk individuals.
Identify high-risk liver recipients
Evidence highlighted renal replacement therapy around transplantation, retransplantation, and transplant for fulminant hepatic failure. The agent decision must include interactions and organ toxicity.
Recognize lung-transplant uncertainty
The panel makes no recommendation for or against universal, targeted, or preemptive strategies in lung transplant because evidence remains insufficient. Local epidemiology and patient factors guide practice.
Choose the agent deliberately
When liver-transplant prophylaxis is required, the update suggests an echinocandin or newer mold-active triazole rather than amphotericin formulations or itraconazole, while emphasizing interactions and bioavailability.
Quick check
Lesson
Close Every Aspergillosis Loop
A defensible plan links syndrome, immune host, imaging, organism evidence, exact agent, exposure, toxicity, resistance, source control, duration, and future immunosuppression.
- Syndrome
- Host
- Evidence
- Treatment
- Ownership
integrated case
Separate exposure, airway disease, chronic cavities, and tissue invasion before selecting evidence and therapy.
Name the syndrome
Document whether the working model is allergic, colonizing, aspergilloma, chronic pulmonary, invasive pulmonary, or extrapulmonary disease and list the evidence required to confirm it.
Name the treatment phase
Separate prophylaxis, empiric or preemptive therapy, primary treatment, salvage, oral transition, chronic suppression, and secondary prophylaxis.
Name the exposure system
Record exact drug, formulation, route, loading, weight basis, organ adjustments, TDM plan, interactions, toxicity checks, adherence, access, and administration.
Name follow-through
Assign cultures, pathology, susceptibility, biomarkers, imaging, procedures, immune recovery, duration, transition, and relapse surveillance to specific clinicians and dates.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.